Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses?

Antimicrobial agents and chemotherapy - 1 May 2005

Kinzig-Schippers Martina, Tomalik-Scharte Dorota, Jetter Alexander, Scheidel Bernhard, Jakob Verena, Rodamer Michael, Cascorbi Ingolf, Doroshyenko Oxana, Sörgel Fritz, Fuhr Uwe

Abstract excerpt

Isoniazid is metabolized by the genetically polymorphic arylamine N-acetyltransferase type 2 (NAT2). A greater number of high-activity alleles are related to increased acetylation capacity and in some reports to low efficacy and toxicity of isoniazid. The objective of this study was to assess individual isoniazid exposure based on NAT2 genotype to predict a personalized therapeutic dose. Isoniazid was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acetylation
Share to Administration, Oral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antitubercular Agents

Share to Arylamine N-Acetyltransferase

Share to Biotransformation

Share to Injections, Intravenous

Share to Isoniazid

Share to Software

Source

Open in PubMed Open full text

Identifiers

PMID: 15855489
DOI: 10.1128/AAC.49.5.1733-1738.2005
PMCID: PMC1087660

Genes

NAT2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses?PMID 15855489Read ↗

Dose-escalation study of isoniazid in healthy volunteers with the rapid acetylator genotype of arylamine N-acetyltransferase 2.Semantic proximity Read ↗

Genetic polymorphism in N-Acetyltransferase (NAT): Population distribution of NAT1 and NAT2 activity.Semantic proximity Read ↗

Study of NAT2 gene polymorphisms in an Indian population: association with plasma isoniazid concentration in a cohort of tuberculosis patients.Semantic proximity Read ↗

Arylamine N-acetyltransferase acetylation polymorphisms: paradigm for pharmacogenomic-guided therapy- a focused review.Semantic proximity Read ↗

Estimating N-acetyltransferase metabolic activity and pharmacokinetic parameters of isoniazid from genotypes in Chinese subjects.Semantic proximity Read ↗

A pilot study to investigate the utility of NAT2 genotype-guided isoniazid monotherapy regimens in NAT2 slow acetylators.Semantic proximity Read ↗

Influence of N-acetyltransferase 2 (NAT2) genotype/single nucleotide polymorphisms on clearance of isoniazid in tuberculosis patients: a systematic review of population pharmacokinetic models.Semantic proximity Read ↗

A proposal for an individualized pharmacogenetic-guided isoniazid dosage regimen for patients with tuberculosis.Semantic proximity Read ↗

A rapid pharmacogenomic assay to detect <i>NAT2</i> polymorphisms and guide isoniazid dosing for tuberculosis treatmentSemantic proximity Read ↗

Expression and genotype-dependent catalytic activity of N-acetyltransferase 2 (NAT2) in human peripheral blood mononuclear cells and its modulation by Sirtuin 1.Semantic proximity Read ↗

Correlation of N-acetyltransferase 2 genotype with isoniazid acetylation in Polish tuberculosis patients.Semantic proximity Read ↗

Acetylation Variability in Elderly Tunisians: Implications for Isoniazid Dose Individualization.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.